After moving 1.2% during today's afternoon session, Biogen is now trading at a price of $240.31 per share. On average, analysts give it a target price of $330.76.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Potential Biogen Investors Should Analyze the Following:
Biogen has moved -14.0% over the last year.
The company has a price to earnings growth (PEG) ratio of 33.68. A number between 0 and 1 could mean that the market is undervaluing Biogen's estimated growth potential
Its Price to Book (P/B) ratio is 2.41
Understanding Biogen's Operating Margins
|Date Reported||Total Revenue ($ k)||Operating Expenses ($ k)||Operating Margins (%)||YoY Growth (%)|
Over the last 6 years, Biogen's operating margins have averaged 37.3%, which is better than the 15.02% Biotechnology industry average. We also note that the company's operating margins have a high coefficient of variability at 73.6%. However the firm's margins are declining at a compounded yearly rate of -5.5%.